Joe Sandys

Joe’s practice focuses primarily on the life sciences sector, advising pharmaceutical, biotechnology and medical technology companies in a wide range of domestic and international intellectual property-based transactions.

He has particular experience in representing life sciences and technology companies in licensing and merger and acquisition transactions, together with the associated operational intellectual property, regulatory and supply chain issues

Notable experience includes advising:

• Silence Therapeutics on its $1.3 billion collaboration with Hansoh Pharma to develop therapeutics Leveraging Silence’s mRNAi GOLD™ Platform 
  
• Silence Therapeutics on a strategic collaboration with AstraZeneca to discover, develop and commercialise small interfering RNA therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases
• Artios, a leading independent DDR company developing novel cancer therapies, on its collaboration with Merck that will see the latter opt into exclusive development and commercialization of compounds on up to 8 targets
• Bavarian Nordic on its €955 million acquisition of the manufacturing and global rights to two commercial vaccines - Rabipur/RabAvert and Encepur – from GlaxoSmithKline
• Hummingbird Bioscience on the development of a COVID-19 response program to initiate a clinical trial to study the safety and efficacy of its experimental SARS-CoV-2 antibody therapy, HMBD-115
• Coalition for Epidemic Preparedness Innovations (CEPI) on a number of funding agreements, including with Themis Bioscience for the development of a vaccine against Chikungunya and with Oxford University and Janssen Vaccines for the development of adenoviral vectored vaccines against MERS, Nipah and Lassa
• Immedica Pharma on its license and supply agreement for pegzilarginase, which is being investigated as a treatment for Arginase 1 Deficiency.
• Medivir AB on its exclusive out-license to IGM Biosciences of birinapant, a clinical-stage SMAC mimetic
• Syneos Health, the only fully integrated biopharmaceutical solutions organisation, on the acquisition of Illingworth Research Group, a leading provider of clinical research home health services